BRISBANE, Calif.--(BUSINESS WIRE)--June 26, 2006--Tercica, Inc. (Nasdaq:TRCA - News) -- Tercica, Inc. (Nasdaq:TRCA - News) today provided an update on the first six months of the Increlex(TM) (mecasermin (rDNA origin) injection) launch in severe primary insulin-like growth factor-1 deficiency (severe Primary IGFD).
